Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS: Drotrecogin Alfa in Early Stage Severe Sepsis
NCT00568737Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of drotrecogin alfa in sepsis, sponsored by Eli Lilly and Company. Started Nov 2002; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00568737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568737.